ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,086.75
0.61%
US Tech 100
20,914.00
1.16%
다우존스 지수
45,040.20
0.75%
Bitcoin
98,944.85
3.09%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. IO Biotech Inc (IOBT)

  7. IO Biotech Inc (IOBT) 뉴스

IOBT

IO Biotech (IOBT)

IO Biotech Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IOBT
일자시간출처헤드라인심볼기업
2024/11/1306:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
2024/11/1221:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
2024/11/1221:05GlobeNewswire Inc.IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
2024/11/1206:05GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
2024/11/0800:00GlobeNewswire Inc.IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNASDAQ:IOBTIO Biotech Inc
2024/10/0422:00GlobeNewswire Inc.IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:IOBTIO Biotech Inc
2024/09/1415:30GlobeNewswire Inc.IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerNASDAQ:IOBTIO Biotech Inc
2024/08/3105:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
2024/08/3105:05GlobeNewswire Inc.IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaNASDAQ:IOBTIO Biotech Inc
2024/08/2705:05GlobeNewswire Inc.IO Biotech Announces Participation in Upcoming Investor ConferencesNASDAQ:IOBTIO Biotech Inc
2024/08/1405:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
2024/08/1320:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
2024/08/1320:05GlobeNewswire Inc.IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
2024/07/2605:05GlobeNewswire Inc.IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024NASDAQ:IOBTIO Biotech Inc
2024/06/1205:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
2024/06/0805:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
2024/06/0805:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOBTIO Biotech Inc
2024/05/2321:30GlobeNewswire Inc.IO Biotech to Present at Jefferies Global Healthcare ConferenceNASDAQ:IOBTIO Biotech Inc
2024/05/1421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
2024/05/1421:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOBTIO Biotech Inc
2024/05/1420:55GlobeNewswire Inc.IO Biotech Reports First Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:IOBTIO Biotech Inc
2024/04/2505:30GlobeNewswire Inc.IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:IOBTIO Biotech Inc
2024/04/1521:30GlobeNewswire Inc.IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessNASDAQ:IOBTIO Biotech Inc
2024/04/1001:00GlobeNewswire Inc.IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103NASDAQ:IOBTIO Biotech Inc
2024/04/0521:30GlobeNewswire Inc.IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business OfficerNASDAQ:IOBTIO Biotech Inc
2024/03/1205:56Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IOBTIO Biotech Inc
2024/03/0706:11GlobeNewswire Inc.IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IOBTIO Biotech Inc
2024/03/0607:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IOBTIO Biotech Inc
2024/03/0606:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOBTIO Biotech Inc
2024/03/0606:40GlobeNewswire Inc.IO Biotech Announces 2023 Fourth-Quarter and Year-End ResultsNASDAQ:IOBTIO Biotech Inc
 검색 관련기사 보기:NASDAQ:IOBT

최근 히스토리

SPI
SP500
S&P 500
FX
USDGBP
US Dollar vs Sterling
AMEX
XLF
Financial Select Sector
NASDAQ
MSFT
Microsoft
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
XRPUSD
Ripple
NYSE
KO
Coca Cola
NYSE
NKE
Nike
CCOM
SILVER
SILVER
COIN
BTCUSD
Bitcoin
USOTC
BASFY
BASF (QX)
NASDAQ
AAPL
Apple
AMEX
SPY
SPDR S&P 500
CCOM
US100
US Tech 100
NYSE
BAC
Bank of America
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유